Temporal Concept – Page 23

Novartis Reveals Sustained Efficacy and Safety of Fabhalta in Patients Switching from Anti-C5 Therapies for Paroxysmal Nocturnal Hemoglobinuria (PNH)

9 months ago talkbio0Tagged anti-C5, Avoidance, Blood Transfusion, Effectiveness, Fabhalta, Hemoglobin improvement, Iptacopan, Paroxysmal, Paroxysmal nocturnal hemoglobinuria, PNH, Safety, Switching therapies

Fabhalta (iptacopan), Paroxysmal Nocturnal Hemoglobinuria (PNH), Anti-C5 therapies, Efficacy and safety, Switching therapies, Hemoglobin improvement, Transfusion avoidance

Limited Access to Mounjaro: England’s NHS Rolls Out Obesity Drug with Phased Approach

9 months ago talkbio0Tagged Access, England, Mounjaro, Nance-Horan syndrome, Obesity, Phase, rollout, Weight Loss Medication

Mounjaro, obesity drug, NHS England, limited access, phased rollout, weight loss medication, tirzepatide.

Protara’s TARA-002 Cell Therapy Shows Exceptional Promise in Treating Non-Muscle Invasive Bladder Cancer

9 months ago talkbio0Tagged BCG-Naïve, BCG-Unresponsive, Carcinoma of urinary bladder, invasive, Cell Therapy, Clinical Trials, Lyophilized Inactivated Group A Streptococcus TARA-002, Non-Muscle, Non-Muscle Invasive Bladder Neoplasms, Phase 2, Protara Therapeutics

Protara Therapeutics, TARA-002, Non-Muscle Invasive Bladder Cancer (NMIBC), Phase 2 ADVANCED-2 trial, Cell therapy, BCG-Unresponsive, BCG-Naïve

Healthcare M&A and IRA Price Negotiations: Key Trends to Watch Amidst Political Shifts

9 months ago talkbio0Tagged Acquisitions, Drug Industry, drug price, Healthcare M&A, Inflation, Ira (eukaryote), Mediation, Medicare, mergers, Negotiation Program, Prices, trends qualifier

Healthcare M&A, IRA Price Negotiations, Medicare Drug Price Negotiation Program, Inflation Reduction Act, Pharmaceutical Industry Trends, Mergers and Acquisitions Outlook 2024

Relay Therapeutics Partners with Elevar Therapeutics in $500M Deal for Lirafugratinib in Rare Cancer Treatment

9 months ago talkbio0Tagged biotech, Cancer Therapeutic Procedure, Cholangiocarcinoma, Infrequent, Lirafugratinib, Partnership, Relay Therapeutics

Relay Therapeutics, Elevar Therapeutics, Lirafugratinib, FGFR2-Driven Cholangiocarcinoma, Rare Cancer Treatment, Biotech Partnership

FDA Rejects Govorestat for Classic Galactosemia, Citing Clinical Deficiencies

9 months ago talkbio0Tagged clinical deficiencies, disease drug approval, Galactosemias, Govorestat, Infrequent, Rejection, United States Food and Drug Administration

FDA rejection, govorestat, classic galactosemia, Applied Therapeutics, rare disease drug approval, clinical deficiencies

Sarepta Therapeutics and Arrowhead Pharmaceuticals Enter $825M Global Licensing and Collaboration Agreement for Multiple siRNA Programs

10 months ago talkbio0Tagged Arrowhead, Collaboration Agreement, gene therapy, Global Licensing, Hereditary Diseases, Infrequent, Interferes with, RNA, RNA, Small Interfering

Sarepta Therapeutics, Arrowhead Pharmaceuticals, siRNA programs, Global Licensing and Collaboration Agreement, Rare genetic diseases, Gene therapy, RNA interference